Journal article · 2026 · Open access

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023)

Courtney Levy, Sarah Sauchelli, Jessica L. Abel, Mia Wraight, Dorothee Oberdhan, Lynda C. Doward, Ari Gnanasakthy

Value in Health, 29(9), 1672–1682 · Published 24 June 2026 · DOI 10.1016/j.jval.2026.04.017

Open PDFView at the publisherCite this paper

In brief

“Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023)” is a 2026 journal article by Courtney Levy and 6 co-authors, published in Value in Health. OpenAlex counts 0 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at Value in Health.

Citations
0
References
12
Authors
7

Abstract

OBJECTIVES: Inclusion of patient-reported outcome (PRO) data in Summaries of Product Characteristics (SmPCs) and package leaflets published by the European Medicines Agency (EMA) is critical to communicate patient-reported value of new medicines. This study aimed to identify key issues in the incorporation and interpretation of PROs in clinical trials that may hinder approval of PRO-related language in SmPCs/package leaflets. METHODS: Indications of new medicines recommended for approval by the EMA between 2020 and 2023 were identified. The Public Assessment Reports, SmPCs, and package leaflets were systematically reviewed. Information pertaining to inclusion of PROs in confirmatory trial(s) and PRO-related reviewer comments were extracted and categorized. RESULTS: Of 167 indications examined, 58 (35%) included PRO-related statements of treatment effect in the SmPC/package leaflet. Critical comments by EMA reviewers focused on study design and PRO data robustness, concerns about statistical analysis, data quality, and PRO measure appropriateness. Such critiques did not always lead to exclusion of PROs from the SmPC, particularly when PRO endpoints were multiplicity-controlled. PRO data collected in unblinded trials-sometimes unavoidable-were often deemed acceptable if multiplicity-controlled. CONCLUSIONS: Review findings emphasize that thoughtful selection of PRO measures, their implementation in trial protocol design, and appropriate statistical analysis planning can strengthen the credibility of PRO results in confirmatory trials, which is critical for supporting the approval of PRO-based value messaging. Insights generated may be used by marketing authorization applicants to support a favorable assessment of PRO data by the EMA.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Levy, C., Sauchelli, S., Abel, J. L., Wraight, M., Oberdhan, D., Doward, L. C., & Gnanasakthy, A. (2026). Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023). Value in Health, 29(9), 1672–1682. https://doi.org/10.1016/j.jval.2026.04.017

MLA 9

Levy, Courtney, et al. “Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023).” Value in Health, vol. 29, no. 9, 2026, pp. 1672–1682. https://doi.org/10.1016/j.jval.2026.04.017.

Chicago

Levy, Courtney, Sarah Sauchelli, Jessica L. Abel, Mia Wraight, Dorothee Oberdhan, Lynda C. Doward, and Ari Gnanasakthy. 2026. “Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023).” Value in Health 29 (9): 1672–1682. https://doi.org/10.1016/j.jval.2026.04.017.

Harvard

Levy, C. et al. (2026) ‘Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023)’, Value in Health, 29(9), pp. 1672–1682. doi:10.1016/j.jval.2026.04.017.

IEEE

C. Levy et al., “Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023),” Value in Health, vol. 29, no. 9, pp. 1672–1682, 2026, doi: 10.1016/j.jval.2026.04.017.

BibTeX

@article{levy2026critical,
  title     = {{Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023)}},
  author    = {Levy, Courtney and Sauchelli, Sarah and Abel, Jessica L. and Wraight, Mia and Oberdhan, Dorothee and Doward, Lynda C. and Gnanasakthy, Ari},
  journal   = {Value in Health},
  year      = {2026},
  volume    = {29},
  number    = {9},
  pages     = {1672--1682},
  doi       = {10.1016/j.jval.2026.04.017},
  url       = {https://doi.org/10.1016/j.jval.2026.04.017}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • patient-reported outcomes
  • regulatory submissions
  • European Medicines Agency
  • Summary of Product Characteristics
  • package leaflets
  • confirmatory trials
  • multiplicity control
  • unblinding

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Levy, C., Sauchelli, S., Abel, J. L., Wraight, M., Oberdhan, D., Doward, L. C., & Gnanasakthy, A. (2026). Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023). Value in Health, 29(9), 1672–1682. https://doi.org/10.1016/j.jval.2026.04.017

How many times has this paper been cited?

0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Value in Health: sign in and open the PDF from this page.

Who wrote this paper?

Courtney Levy, Sarah Sauchelli, Jessica L. Abel, Mia Wraight, Dorothee Oberdhan, Lynda C. Doward, Ari Gnanasakthy.

What is the DOI of this paper?

10.1016/j.jval.2026.04.017, permanently at https://doi.org/10.1016/j.jval.2026.04.017. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.